Precigen's PAPZIMEOS: First FDA-Approved Treatment for Recurrent Respiratory Papillomatosis
- Precigen's PAPZIMEOS is the first FDA-approved treatment for recurrent respiratory papillomatosis, marking a significant biopharmaceutical milestone.
- Over 200 patients are enrolled in the patient hub for PAPZIMEOS, indicating strong demand and rapid adoption by healthcare providers.
- Precigen is expanding globally with European approval for PAPZIMEOS, enhancing international access to this innovative treatment.
Precigen Achieves Milestone with FDA Approval of PAPZIMEOS
Precigen, Inc. makes significant strides in the biopharmaceutical sector with the FDA’s approval of PAPZIMEOS (zopapogene imadenovec-drba), marking it as the first and only treatment available for adults suffering from recurrent respiratory papillomatosis (RRP). This landmark approval, achieved in August 2025, not only highlights the innovative capabilities of Precigen but also underscores the urgent need for effective therapies in addressing rare diseases. RRP, a condition characterized by benign tumors in the respiratory tract, has long lacked targeted treatment options, and PAPZIMEOS represents a revolutionary step forward in patient care.
The commercialization process for PAPZIMEOS is gaining momentum, with prescriptions being filled nationwide. Recent data shows that more than 200 patients are now enrolled in the patient hub—an impressive doubling since November, reflecting strong demand from both major medical centers and community practices. This rapid adoption indicates that healthcare providers are eager to offer this novel treatment to their patients, driven by the compelling safety and efficacy data supporting its use. Helen Sabzevari, PhD, President and CEO of Precigen, emphasizes that this swift uptake is a testament to the therapy's potential to redefine treatment paradigms for RRP, ultimately improving patient outcomes across the board.
In addition to its domestic success, Precigen is poised for global expansion, with the European Medicines Agency validating the Marketing Authorization Application for PAPZIMEOS. This validation opens avenues for international availability, promising to extend the therapy's reach to patients in need across Europe. Furthermore, Precigen’s robust infrastructure ensures that its comprehensive manufacturing and supply chain capabilities are ready to meet both current and future demand for PAPZIMEOS. As Phil Tennant, Chief Commercial Officer, points out, the company’s proactive field engagement across targeted centers is nearly complete, positioning Precigen as a leader in the innovative precision medicine landscape. With sustained capital resources expected to support operations until the company reaches cash flow break-even, Precigen is solidifying its market presence as it looks ahead.
As part of its ongoing commitment to advancing innovative therapies, Precigen is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. This engagement will further highlight the company’s dedication to reshaping the treatment landscape for RRP and other conditions through cutting-edge precision medicines. With PAPZIMEOS at the forefront, Precigen is not only addressing unmet medical needs but is also setting a new standard for how rare diseases are treated in the future.
